IL6 and stroke disorder: This result was consistent with the findings of the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy Study) trial, in which an independent relationship was identified between IL-6 and a higher risk of stroke and major bleeding independent of clinical risk factors, even after adjusting for cardiovascular biomarkers to attenuate the prognostic value (29).